Bluebird Bio Inc (BLUE) 166.51 $BLUE bluebird bio

New Post Public Reply Private Reply Replies (0) Message Board

Aug 5, 2015 at 11:35 PM

Bluebird Bio Inc (BLUE) 166.51 $BLUE

bluebird bio Announces Participation at the 2015 Wedbush PacGrow Healthcare Conference
Business Wire - Wed Aug 05, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE) today announced that members of the management team will participate in the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015, with a presentation at 9:10 a.m. ET. The conference is being held at Le Parker Meridien Hotel in New York City.
BLUE: 166.51 (+2.04)

bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 6:27AM CDT
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy?
BLUE: 166.51 (+2.04)

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34)

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), AMGN: 176.44 (+1.64), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34), CELG: 132.72 (+1.64)

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), NBIX: 50.44 (+0.88), ISIS: 54.52 (-0.78), SRPT: 32.73 (-0.02), RCPT: 228.97 (+0.97)

What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 166.51 (+2.04)

Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)

Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)

An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)

Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)

Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)

Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)

Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 166.51 (+2.04), CELG: 132.72 (+1.64)

For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 166.51 (+2.04)

Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT

BLUE: 166.51 (+2.04), DRNA: 11.54 (-0.43), ALNY: 127.73 (+1.85), TKMR: 10.83 (+0.58), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)

Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 166.51 (+2.04), HZNP: 35.06 (+0.06), AAL: 42.96 (+0.22), SDRL: 7.91 (+0.01), HNT: 69.03 (+0.38)

Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT

AGTC: 17.91 (-0.47), BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), AMGN: 176.44 (+1.64), JUNO: 46.67 (+0.17), SRNE: 20.59 (-0.16), XLRN: 28.86 (-0.15), CELG: 132.72 (+1.64)

Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 166.51 (+2.04), KITE: 76.50 (+2.96), ADMS: 24.61 (-0.12), ACHN: 8.11 (unch)

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 166.51 (+2.04), GILD: 118.66 (-0.21), MNKD: 4.19 (+0.04), PBYI: 90.21 (+1.76), KERX: 7.51 (+0.17), CELG: 132.72 (+1.64)

Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 166.51 (+2.04), KITE: 76.50 (+2.96), CLLS: 35.00 (+0.22), JUNO: 46.67 (+0.17), CYAD: 55.06 (-0.85), CELG: 132.72 (+1.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 298

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...